| JaLCDOI | 10.18926/AMO/54499 |
|---|---|
| フルテキストURL | 70_4_243.pdf |
| 著者 | Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| 抄録 | Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation. |
| キーワード | vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-08 |
| 巻 | 70巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 243 |
| 終了ページ | 253 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27549668 |
| Web of Science KeyUT | 000384748600003 |
| タイトル（別表記） | A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy |
|---|---|
| フルテキストURL | 127_127.pdf |
| 著者 | 木浦 勝行| 堀田 勝幸| 佐藤 晃子| 大橋 圭明| 二宮 崇| 南 大輔| 田端 雅弘| 久保 寿夫| 加藤 有加| 平田 泰三| |
| キーワード | 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2015-08-03 |
| 巻 | 127巻 |
| 号 | 2号 |
| 開始ページ | 127 |
| 終了ページ | 132 |
| ISSN | 0030-1558 |
| 関連URL | isVersionOf https://doi.org/10.4044/joma.127.127 |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2015 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.127.127 |
| NAID | 130005096256 |
| 著者 | Yasugi, Masayuki| Takigawa, Nagio| Ochi, Nobuaki| Ohashi, Kadoaki| Harada, Daijiro| Ninomiya, Takashi| Murakami, Toshi| Honda, Yoshihiro| Ichihara, Eiki| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| 発行日 | 2014-08-15 |
| 出版物タイトル | Experimental Cell Research |
| 巻 | 326巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |